Sabar Karimah Es 4
4 · CAPRICOR THERAPEUTICS, INC. · Filed Apr 3, 2026
Research Summary
AI-generated summary of this filing
Capricor (CAPR) Director Sabar Karimah Exercises and Sells Shares
What Happened
- Director Sabar Karimah exercised/conversion of a derivative for 7,529 shares (recorded as an "M" transaction) at $3.18 per share (total cost $23,942) and immediately sold those 7,529 shares in an open-market sale at $32.00 per share for $240,928 on 2026-04-02. The filing also records the corresponding disposition of the derivative instrument (7,529 shares, $0.00 value).
- This is a sale of shares following an exercise/conversion — typically routine insider liquidity rather than a new purchase (not a bullish purchase signal).
Key Details
- Transaction date: April 2, 2026; Form 4 filed April 3, 2026 (timely).
- Exercise/Acquisition: 7,529 shares @ $3.18 = $23,942 (transaction code M).
- Sale/Disposition: 7,529 shares @ $32.00 = $240,928 (transaction code S).
- Net proceeds before taxes/fees (proceeds minus exercise cost): roughly $216,986.
- Footnotes: F1 — shares sold pursuant to a 10b5-1 trading plan adopted Dec 2025; F2 — shares vested 1/48th on the first day of each month beginning Feb 1, 2022.
- Shares owned after transaction: not specified in the excerpt of the filing provided.
Context
- For derivative transactions: this filing shows an option/derivative was exercised (incurring the $3.18 per-share cost) and the resulting shares were sold in the open market — effectively a cash exercise followed by immediate sale under a pre-existing 10b5-1 plan.
- The 10b5-1 plan note indicates the sale followed a pre-set trading plan (reduces concerns about opportunistic timing).
- No indication this was a gift or a related-party/10% owner transaction in the provided data.
Insider Transaction Report
Form 4
Sabar Karimah Es
Director
Transactions
- Exercise/Conversion
Common Stock
2026-04-02$3.18/sh+7,529$23,942→ 7,529 total - Sale
Common Stock
[F1]2026-04-02$32.00/sh−7,529$240,928→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
[F2]2026-04-02−7,529→ 161 totalExercise: $3.18Exp: 2032-01-03→ Common Stock (7,529 underlying)
Footnotes (2)
- [F1]Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- [F2]Shares vested 1/48th on the first day of each month commencing February 1, 2022.
Signature
/s/ Linda Marban, Attorney-in-Fact|2026-04-03